BioAge dips after unveiling planned $75 mln stock sale

BioAge Labs

21/01/2026 13:42

** BioAge Labs BIOA.O shares down 2% premarket at $20.89 as biopharma co seeks equity raise

** Emeryville, California-based BIOA late Tues announced $75 mln stock offering

** Co intends to use net offering proceeds to fund research, clinical development and manufacturing of its product candidates, including lead candidate BGE-102, a small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, among other uses

** Goldman Sachs, Piper Sandler and Citigroup joint bookrunners

** Co has ~35.9 mln shares outstanding for roughly $765 mln market cap

** BIOA shares on Tues closed up nearly 6%, putting them up 61% to start 2026. Stock has rallied four-fold over the past three months

** 1 analyst rates the stock "strong buy", 3 rate "hold" with PTs ranging from $9-$15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))